Antibiotics closed an agreement with American Metabolix to produce resin of biopolymer Mirel in León
Leon, 29 Jul. (EUROPA PRESS)-
Antibioticos S.A. company and the American Metabolix Inc. have signed an agreement that will enable the Spanish company to produce resin of biopolymer Mirel at its facilities in León.
Under the terms of the agreement, Metabolix will begin work immediately with antibiotics to carry out a series of previous works of validation at level of the process of fermentation and recovery of this bio-based plastic product taking advantage of the equipment and the experience of the Spanish factory.
Both companies, as detailed antibiotics in a connected recgido by Europa Press, plan a later settlement of final contract for the manufacture of this product.
Metabolix is a North American pioneer in the field of biotechnology and ' experienced' in providing sustainable solutions in the plastics industry, energy and chemical products that will be proprietary resin that occurs during the process of validation.
'This agreement with antibiotics represents an important step forward in the establishment of a new chain for Mirel biopolymers to supply our clients around the world and to continue the development of products of high added value in our applications,' said President and Chief Executive Officer of Metabolix, Richard P. Eno, who added that antibiotics is located in a country of the European Unionnear many of its objectives 'customers'.
The head of the US firm has shown, according to the same sources, 'impressed' with 'history, know-how and facilities' antibiotics 'and their teams are well adapted to the manufacturing process we use to produce biopolymers Mirel commercial-scale'.
For his part, Daniele Pucci di Benisichi has ensured that the agreement meets 'experience and technical capacity' of antibiotics with the technology and the processes of Metabolix 'in a manner consistent with the values and vision of both companies'. Part 2 to follow:
The first step of our common work will be to validate its technology in our facilities and then we continue with the formalization of a manufacturing agreement contract. Antibiotics is a very demanding and selective approach to new projects and new partners, and we are especially pleased to work with Metabolix to delve into our momentum of sustainable technologies and diversification of our portfolio of businesses ', highlighted.